Summit Therapeutics stock extends weekly decline to $13.56 amid bearish momentum

Traders Union
All News
Companies
Summit Therapeutics drops 9.48% today

Highlights

SMMT extends its multi-week decline, falling 9.48% today and trading at the lower end of its weekly range.
All major indicators confirm persistent bearish momentum, with price well below primary moving averages and weak technical sentiment prevailing.
Expected trading range for the coming week is $13.30–$14.90, with probability of a rebound below 20% and risk of testing the $12.55 low if support fails.

Technical weakness as price rejects key moving averages and Ichimoku resistance

SMMT is trading well below the MA-20 ($14.82), MA-50 ($15.29), and especially the MA-200 ($17.33), highlighting strong downside momentum in both the short and long term. The Ichimoku Kijun on D1 sits at $14.72, acting as immediate resistance above the current price. Near-term support is found around the MA-20 ($14.82), with key support at the MA-50 ($15.29). Immediate resistance is the Ichimoku Kijun ($14.72), while key resistance remains the MA-100 ($16.93).

Bearish momentum persists as weekly losses deepen and buyers struggle

MACD on D1 signals strong bearish momentum and is aligned with neutral ADX, indicating a weak but persistent downtrend. RSI is in neutral territory near 51, while Stoch RSI shows mixed signals with overbought and oversold readings across timeframes. CCI holds neutral, and BBP indicates recent buyer dominance on D1, though this is contradicted by the current price action and overall bearish momentum. Awesome Oscillator remains neutral. In today's session, SMMT has fallen 9.48%, extending its decline from last week. SMMT is trading at $13.56, down from last week’s close of $13.81, reflecting a 1.38% loss. The price is now at the bottom of its weekly range, and weekly volatility stands at 16.46%, signaling a steady decline from the high.

Downside favored as bearish signals outweigh slim recovery prospects

For the coming week, the adjusted expected price range is $13.30–$14.90, keeping within 10% of the current price and reflecting ongoing volatility yet respecting support above the 52-week low of $12.55 and well below the 52-week high of $30.98. The probability of a price increase is very low (less than 20%), as all W1 indicators (RSI, ADX, MACD, MA-50) point bearish or neutral, making a further decline the more likely scenario. Baseline scenario: SMMT trades sideways within the $13.30–$14.90 band. Bullish scenario: a break above $14.72–$14.90 resistance could trigger a move toward $15.29, but this is currently unlikely. Bearish scenario: a breakdown below $13.30 could open space for a test of the 52-week low near $12.55.

Loading...

The tweet was deleted by the author.

But we saved everything 🙂.

Earlier, analysts noted that Summit Therapeutics was exhibiting persistent bearish momentum despite some short-term rebounds. As the current market environment unfolds, attention should remain on whether buying interest materializes to shift sentiment, with traders advised to closely monitor for signs of renewed downside risk.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.